vision history team
SAMPLING's mission is to couple health related decisions to their effects at the single cell level. It is inspired by the founders’ academic and professional efforts to extend what is measurable and to derive what must be measured.
The human body is a complex system that cannot be quantified exhaustively or heuristically. Clinical diagnosis today is an imprecise art. On average, diagnosis of rare diseases is 5 years delayed with 50% of delays impacting the outcome. Misdiagnosis is far too common with a 66% likelihood of disagreement between experts. We are stuck with symptoms based medicine.
The nature of physiological data is to blame. Decisions today are based on fuzzy variables (tired, drowsy, weak, tingling, itchy, etc.). Better decisions will require precise knowledge regarding the fundamental physiological units of our bodies, CELLS.
Sampling Human is named for the changing paradigm of human biopsy, wherein standard tissue sampling is replaced by single cell diagnostics. The company was founded in 2016 to elevate the field beyond genetic analysis to routinely provide complex single cell data.
Thanks to the backing of a prominent central European investment group BPD partners a.s. (Draslovka, DIANA biotech, Nanuncio, Ginkgo Bioworks, Scipher Medicine, Q2Pharma) as well as support from top Czech research institutions UWB and IOCB, SAMPLING has in its short existence developed a portfolio of single cell technologies that redefine the implications of single cell data in practice.
With follow-on support from the Czech Ministry of Industry, and in collaboration with the Charles University Hospital, SAMPLING is currently validating these technologies in clinical workflows.
We are a diverse group interested in enabling change and excited by unprecedented innovations. We operate as a true team insisting on empowering all its members by matching skills and passions to projects. We emerged from Central Europe, but we identify ourselves as members of the global community.
Sampling Human harnesses global innovation potential with state-of-the-art facilities in San Francisco and Prague. In addition, we are connected to a network of clinical institutions and core facilities that give us the power to engineer, discover, and validate single cell technologies and biomarkers with unprecedented speed and depth.